Quintiles, Quest Diagnostics form JV

Upon closing of the transaction, Quintiles will own 60 percent and Quest Diagnostics will own 40 percent of the joint venture (JV).

joint-ventures-239

(Photo Courtesy: www.referenceforbusiness.com)

Quintiles and Quest Diagnostics announced a definitive agreement to form a global clinical trials laboratory services business.

The transaction, which is subject to standard and customary closing conditions, is anticipated to close in the third quarter of 2015.

The financial terms of this transaction were not disclosed.

The new entity will provide customers with the depth of capabilities and end-to-end clinical trial laboratory services required to succeed in the increasingly complex biopharmaceutical industry.

Mr Steve Rusckowski, CEO, Quest Diagnostics added, "For Quest Diagnostics, the joint venture model will enable us to generate growth and value from our clinical trials assets while simultaneously strengthening our focus on our core diagnostic information services business."

 

Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X